A kind of forskolin oxygen bridged ring derivative and preparation method thereof

By reacting forscorin with potassium hydroxide and aryl iodide under specific conditions, a novel structure of oxygen-bridged derivative was solved, and the problem of insufficient anti-tumor activity of existing derivatives was achieved. Effective inhibition demonstrates the potential of new anti-tumor drugs.

CN117362310BActive Publication Date: 2024-12-06GANSU LANWO TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311391234.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-10-25
Publication Date
2024-12-06
Estimated Expiration
2043-10-25

AI Technical Summary

Technical Problem

The existing Forscolin derivatives have insufficient pharmaceutical activity in anti-cancer, lack structural novelty and excellent anti-tumor effects.

Method used

Rearranged products are obtained by reacting forscorin with potassium hydroxide in methanol and reacting with aryl iodide under catalyzed by anhydrous silver acetate, anhydrous copper acetate and palladium acetate to form a structural novelty forss Kolin oxygen bridge derivatives. The process includes reacting with potassium hydroxide in methanol, concentrating, diluting and drying under cooling, followed by reaction in anhydrous dichloroethane with silver acetate, copper acetate, palladium acetate and aryl iodide, by flashing Column chromatography gave a white solid derivative.

Benefits of technology

The obtained forscorin oxygen-bridged derivative has excellent anti-tumor activity, and its cytotoxic activity exceeds that of the original forscorin, showing significant inhibition on human esophageal cancer, colon cancer and lung adenocarcinoma cell lines. It has the potential to develop into anti-tumor drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117362310B_ABST
    Figure CN117362310B_ABST
Patent Text Reader

Abstract

The present invention belongs to the technical field of pharmaceutical chemistry and pharmacology, and relates to a forskolin oxygen bridged ring derivative and a preparation method thereof. The forskolin oxygen bridged ring derivative has a chemical structure shown in formula (I), and forskolin is reacted with potassium hydroxide in methanol to obtain a forskolin rearrangement product 1, and then the forskolin rearrangement product 1 is reacted with an aryl iodide in anhydrous dichloroethane under the catalysis of anhydrous silver acetate, anhydrous copper acetate and palladium acetate to obtain a forskolin oxygen bridged ring derivative (I). The forskolin oxygen bridged ring derivative obtained by the present invention has strong anti-cancer activity and can be used to prepare anti-cancer drugs. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of pharmaceutical chemistry and pharmacology, and in particular to a forskolin oxygen-bridged ring derivative and a preparation method thereof. Background Art

[0002] Forskolin is a diterpenoid compound with important medicinal value in anti-cancer, anti-asthma, anti-hypertension and positive inotropic effects. In addition, forskolin can also interact with certain other proteins, such as glucose transporters and ion channels. The results of pharmacodynamic studies have shown that forskolin can effectively promote the differentiation of neurons and the growth of neurites in the central and peripheral nervous systems, thereby having an important impact on the cardiovascular and cerebrovascular systems, respiratory systems and tumors, and has pharmacological effects such as cardiotonic, anti-asthmatic, anti-tumor, anti-thrombotic and lowering intraocular pressure. It is now clinically used for the treatment of cardiovascular and cerebrovascular diseases, tumors and common diseases of the elderly, with obvious pharmacological effects and broad prospects for clinical application. Summary of the invention

[0003] In view of this, the purpose of the present invention is to chemically transform forskolin and obtain a derivative with novel structure, wherein the derivative has pharmaceutical activity in anti-cancer and other aspects.

[0004] The present invention provides a forskolin oxygen bridged ring derivative, which has a structure shown in general formula (I):

[0005]

[0006] Here, R represents one of phenyl, p-chlorophenyl, p-methoxyphenyl, p-trifluoromethoxyphenyl, p-tert-butylphenyl, p-methylphenyl, p-nitrophenyl and p-cyanophenyl.

[0007] Furthermore, the forskolin oxygen-bridged ring derivative has a structure as shown in any one of Formulas 2a to 2d:

[0008]

[0009] in,

[0010] When R is phenyl, the forskolin oxygen bridged ring derivative is a compound having a structure shown in Formula 2a;

[0011] When R is p-chlorophenyl, the forskolin oxygen bridged ring derivative is a compound having a structure shown in Formula 2b;

[0012] When R is p-methoxyphenyl, the forskolin oxygen bridged ring derivative is a compound having a structure shown in formula 2c;

[0013] When R is p-trifluoromethoxyphenyl, the forskolin oxygen bridged ring derivative is a compound with a structure shown in formula 2d.

[0014] The present invention also provides a method for preparing the oxygen-bridged ring derivative of forskolin, comprising the following steps:

[0015] Forskolin is reacted with potassium hydroxide in methanol to obtain a forskolin rearrangement product 1, and then the forskolin rearrangement product 1 is reacted with an aryl iodide in anhydrous dichloroethane under the catalysis of anhydrous silver acetate, anhydrous copper acetate and palladium acetate to obtain a forskolin oxygen-bridged ring derivative (I).

[0016] Wherein, the reaction formula of the reaction is:

[0017]

[0018] Here, R represents one of phenyl, p-chlorophenyl, p-methoxyphenyl, p-trifluoromethoxyphenyl, p-tert-butylphenyl, p-methylphenyl, p-nitrophenyl and p-cyanophenyl.

[0019] Specifically, the preparation method comprises the following steps:

[0020] (1) Potassium hydroxide is dissolved in methanol, and forskolin is added to react to obtain a first reaction solution. The first reaction solution is cooled, concentrated under reduced pressure, diluted with an organic solvent, washed with water, washed with saturated brine, and anhydrous MgSO 4 Drying, drying under reduced pressure, and then flash column chromatography to obtain a white solid forskolin rearrangement product 1, wherein the molar ratio of forskolin to potassium hydroxide is 1:13;

[0021] (2) dissolving the forskolin rearrangement product 1 in anhydrous dichloroethane, and sequentially adding anhydrous silver acetate, anhydrous copper acetate, palladium acetate and aryl iodide to react to obtain a second reaction solution, cooling the second reaction solution, diluting it with an organic solvent, filtering it, concentrating the filtrate under reduced pressure, and then flash column chromatography to obtain a white solid forskolin oxygen bridged ring derivative 2, wherein the molar ratio of the forskolin rearrangement product 1, anhydrous silver acetate, anhydrous copper acetate, palladium acetate and aryl iodide is 1:1.2:2:0.05:2;

[0022] Wherein, the aryl iodide is one of iodobenzene, p-chloroiodobenzene, p-methoxyiodobenzene, p-trifluoromethoxyiodobenzene, p-tert-butyliodobenzene, p-methyliodobenzene, p-nitroiodobenzene and p-cyaniodobenzene.

[0023] Furthermore, in step (1) of the above preparation method, the reaction temperature is 65° C. and the reaction time is 4 h.

[0024] Furthermore, in step (2) of the above preparation method, the reaction temperature is 72° C. and the reaction time is 18 h.

[0025] Furthermore, in the above preparation method, the organic solvent is at least one of ethyl acetate, dichloromethane and dichloroethane.

[0026] Compared with the prior art, the present application provides a class of forskolin oxygen-bridged ring derivatives and a preparation method thereof. Such compounds have novel structures and excellent anti-tumor activity. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art are briefly introduced below.

[0028] Figure 1 The NMR of the forskolin oxygen bridged ring derivative (1) provided in Example 1 of the present invention is 1 H spectrum;

[0029] Figure 2 The NMR of the forskolin oxygen bridged ring derivative (1) provided in Example 1 of the present invention is 13 C spectrum;

[0030] Figure 3 The NMR of the forskolin oxygen bridged ring derivative (2a) provided in Example 2 of the present invention is 1 H spectrum;

[0031] Figure 4 The NMR of the forskolin oxygen bridged ring derivative (2a) provided in Example 2 of the present invention is 13 C spectrum. DETAILED DESCRIPTION

[0032] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0033] Example 1

[0034] 730 mg (13.0 mmol) of potassium hydroxide was dissolved in methanol (10 ml), and then 410 mg (1.0 mmol) of forskolin was added and reacted at 65°C for 4 hours. The reaction solution was concentrated under reduced pressure, diluted with ethyl acetate (10 ml), and then washed with water and saturated brine in sequence, and anhydrous MgSO 4 The residue was dried and concentrated under reduced pressure, and flash column chromatography (petroleum ether:ethyl acetate=2:1) ​​was used to obtain 336 mg of a white solid, namely, the forskolin rearrangement product 1 (yield 91%).

[0035] 1 HNMR (400MHz, Methanol-d 4 )δ6.06(dd,J=17.5,10.9Hz,1H,H-14),5.16(dd,J=17.5,1.2Hz,1H,H-15),5.04(dd,J =10.9,1.2Hz,1H,H-15),4.16(dd,J=11.0,5.2Hz,1H,H-1),4.01(dd,J=4.1,1.7Hz,1H, H-6),3.64(d,J=1.6Hz,1H,H-7),3.19(d,J=14.4Hz,1H,H-12),1.90(d,J=14.3Hz,1H, H-12),1.79–1.68(m,1H),1.65(d,J=4.1Hz,1H,H-5),1.64–1.60(m,1H),1.52(s,3H,CH 3 ),1.48(s,3H,CH 3 ),1.47(s,3H,CH 3 ),1.34–1.28(m,2H),1.26(s,3H,CH 3 ),0.98(s,3H,CH 3 ). 13 CNMR(100MHz,MeOD)δ143.89,111.35,106.48,91.76,90.54,88.51,88.44,71.18,6 4.92,47.66,45.98,44.38,40.55,33.31,30.00,28.38,26.45,24.95,23.14,13.44.

[0036] Example 2

[0037] 368 mg (1.0 mmol) of forskolin rearrangement product 1 was dissolved in anhydrous dichloroethane (10 ml), and 200 mg (1.2 mmol) of anhydrous silver acetate, 363 mg (2.0 mmol) of anhydrous copper acetate, 12 mg (0.05 mmol) of palladium acetate, and 408 mg (2.0 mmol) of iodobenzene were added in sequence, and the mixture was reacted at 72°C for 18 hours. The reaction solution was diluted with ethyl acetate (10 ml), filtered, and the filtrate was washed with water, saturated brine, and anhydrous MgSO 4 The residue was dried and concentrated under reduced pressure, and flash column chromatography (petroleum ether:ethyl acetate=8:1) was used to obtain 321 mg of a white solid, namely, the oxygen-bridged ring derivative of forskolin 2a (yield 73%).

[0038] 1HNMR(400MHz,Chloroform-d)δ7.38–7.27(m,4H,ArH),7.26–7.21(m,1H,ArH),6.46(d,J=16.3 Hz,1H,H-15),6.38(d,J=16.3Hz,1H,H-14),5.89(s,1H,OH),4.22(dd,J=10.4,5.7Hz,1H,H-1), 4.13(m,2H,H-6,H-7),3.80(d,J=1.6Hz,1H,OH),3.58(s,1H,OH),3.27(d,J=14.2Hz,1H,H-12) ,2.03(d,J=14.1Hz,2H,H-12,OH),1.72(d,J=3.8Hz,1H,H-5),1.71–1.64(m,2H),1.61(s,3H,CH 3 ),1.59(s,3H,CH 3 ),1.57(s,3H,CH 3 ),1.25(s,3H,CH 3 ),1.11(td,J=13.4,4.9Hz,1H),0.90(s,3H,CH 3 ). 13 CNMR (100MHz, CDCl 3 )δ136.22,134.87,128.69,127.80,127.71,126.41,106.66,91.67,91.59,88.66,88.46,71.69,66.46, 48.00,47.24,44.73,40.71,33.62,30.89,29.76,27.18,25.60,24.19,14.38.HRMS(ESI):m / zcalcdforC 26 H 36 O 6 Na:467.2410; found:467.2404[M+Na] + .

[0039] Embodiment 3-5

[0040] According to the method of Example 2 above, iodobenzene was replaced with p-chloroiodobenzene, p-methoxyiodobenzene and p-trifluoromethoxyiodobenzene in sequence to prepare compounds 2b-2d.

[0041] Listed below are the physicochemical data of compounds 2b-2d:

[0042] 2b: Yield 70%. 1HNMR(400MHz, Chloroform-d) δ 7.42–7.21 (m, 4H, ArH), 6.41 (d, J=16.2 Hz, 1H, H-15), 6.34 (d, J=16.2 Hz, 1H, H-14), 5.81 (s, 1H, OH), 4.19 (td, J=6.8, 3.4 Hz, 1H, H-1), 4.12 (d, J=3.8 Hz, 1H, H-6), 3.90 (s, 1H, OH), 3.79 (d, J=1.7 Hz, 1H, H-7), 3.33 (s, 1H, OH) 3.23 (d, J=14.2 Hz, 1H, H-12), 2.01 (d, J=14.1 Hz, 1H, H-12), 1.91–1.84 (m, 1H), 1.76–1.68 (m, 1H), 1.67 (d, J=3.8 Hz, 2H, H-5, CH 2 ), 1.59 (s, 4H), 1.58 (s, 3H, CH 3 ), 1.55 (s, 3H, CH 3 ), 1.24 (s, 3H, CH 3 ), 1.05 (td, J=13.2, 4.8 Hz, 1H), 0.86 (s, 3H, CH 3 ). 13 CNMR(100MHz, CDCl 3 ) δ 135.50, 134.73, 133.43, 128.90, 127.58, 126.47, 106.56, 91.70, 91.58, 88.52, 88.44, 71.71, 66.47, 48.02, 47.23, 44.77, 40.77, 33.62, 30.89, 29.78, 27.29, 25.54, 24.16, 14.32. HRMS(ESI): m / z calcd for C 26 H 35 O 6 NaCl: 501.2020;found: 501.2017 [M+Na] + .

[0043] 2c: Yield 65%. 1HNMR(400MHz, Chloroform-d) δ 7.28 (d, J = 8.5 Hz, 2H, ArH), 6.86 (d, J = 8.6 Hz, 2H, ArH), 6.42 (d, J = 16.2 Hz, 1H, H-15), 6.26 (d, J = 16.2 Hz, 1H, H-14), 5.88 (s, 1H, OH), 4.24 (td, J = 6.8, 3.3 Hz, 1H, H-1), 4.15 (q, J = 4.0, 3.6 Hz, 1H, H-6), 4.06 (s, 1H, OH), 3.82 (s, 3H, OCH 3 ), 3.82–3.80 (m, 1H, H-7), 3.56 (s, 1H, OH), 3.29 (d, J = 14.2 Hz, 1H, H-12), 2.02 (d, J = 14.2 Hz, 1H, H-12), 2.09–1.97 (m, 1H) 1.75 (d, J = 3.9 Hz, 1H, H-5), 1.73–1.67 (m, 2H), 1.62 (s, 3H, CH 3 ), 1.60 (s, 3H, CH 3 ), 1.58 (s, 3H, CH 3 ), 1.27 (s, 3H, CH 3 ), 1.14 (td, J = 13.2, 4.5 Hz, 1H), 0.92 (s, 3H, CH 3 ). 13 CNMR(100MHz, CDCl 3 ) δ 159.29, 132.74, 128.93, 127.59, 127.19, 114.08, 106.65, 91.67, 91.58, 88.74, 88.47, 71.68, 66.49, 55.29, 48.02, 47.29, 44.68, 40.69, 33.63, 30.88, 29.81, 27.20, 25.58, 24.21, 14.34. HRMS(ESI): m / z calcd for C 27 H 38 O 7 Na: 497.2515; found: 497.2514 [M+Na] + .

[0044] 2d: Yield 75%. 1HNMR(400MHz,Chloroform-d)δ7.34(d,J=8.7Hz,2H,ArH),7.16(d,J=8.3Hz,2H,ArH),6.46(d,J=16.2Hz,1H,H-15),6.35(d,J=16.3Hz,1H,H-14),5.85(s,1H,OH),4.21(dd,J=10.4,5.8Hz,1H,H-1),4.14(d,J=4.7Hz,1H,H-6),3.99(s,1H,OH),3.81(d,J=1.6Hz,1H,H-7),3.40(s,1H,OH),3.25(d,J=14.2Hz,1H,H-12),2.03(d,J=14.1Hz,1H,H-12),1.93(d,J=6.5Hz,1H,OH),1.76–1.66(m,2H),1.69(d,J=3.9Hz,1H,H-5),1.61(s,3H,CH 3 ),1.59(s,3H,CH 3 ),1.57(s,3H,CH 3 ),1.31–1.28(m,1H),1.26(s,3H,CH 3 ),1.08(td,J=13.4,4.8Hz,1H),0.88(s,3H,CH 3 ). 13 CNMR(100MHz,CDCl 3 )δ148.73,135.97,135.07,127.71,126.34,121.27,106.69,91.85,91.65,88.59,88.54,71.80,66.55,48.10,47.34,44.90,40.93,33.72,31.02,29.83,27.36,25.66,24.24,14.44.HRMS(ESI):m / zcalcdforC 27 H 35 O 7 NaF 3 :551.2233;found:551.2228[M+Na] + .

[0045] In order to better understand the essence of the present invention, the pharmacological experimental results of the inhibitory effect of the oxygen-bridged ring derivatives of forskolin provided by the present invention on the growth of three tumor cell lines are used below to illustrate its new use in the field of anti-tumor drug research. The pharmacological examples provide partial activity data of representative compounds. It must be noted that the pharmacological examples of the present invention are used to illustrate the present invention rather than to limit the present invention. Simple improvements made to the present invention according to the essence of the present invention all belong to the scope of protection claimed by the present invention.

[0046] Drug Experiment Example 1: Cytotoxicity test of compounds 2a-2d and forskolin on human esophageal cancer cells (TE-13)

[0047] Human esophageal cancer cell TE-13 was cultured in RPMI1640 medium containing 10% fetal bovine serum, 100 U / mL penicillin and 100 U / mL streptomycin. 5×10 cells were plated per well. 3 The concentration was added to a 96-well plate and incubated at 37°C with 5% CO 2 The cells were cultured in a humidified air incubator for 24 hours.

[0048] Compounds 2a-2d were dissolved in DMSO and prepared into 1×10 -2 mol / L stock solution, dilute the stock solution to the corresponding concentration with complete medium, take cells in logarithmic growth phase and inoculate them in 96-well plates, add compound solutions of different concentrations after 24 hours of attachment, set 4 parallel wells for each concentration, add tetramethylthiazolium (MTT) solution after 68 hours of culture, continue to culture for 4 hours, discard the culture medium, add 150μL of dimethyl sulfoxide, shake for 10 minutes, measure the absorbance (A) value at 570nm with an enzyme reader, and calculate the half inhibitory concentration (IC 50 ), as shown in Table 1. According to Table 1, the IC 50 The positive control forskolin has an IC of 4.0 μM for TE-13 cells. 50 It is 52μM.

[0049] Drug Experiment Example 2-3: Cytotoxic activity test of compounds 2a-2d and forskolin on human colon cancer cells (HCT-116) and human lung adenocarcinoma cells (A549).

[0050] The pharmacological experiment was carried out on the growth inhibition of human colon cancer cells (HCT-116) and human lung adenocarcinoma cells (A549) using the method shown in Drug Experiment Example 1, and the half inhibitory concentration (IC 50 ), as shown in Table 1.

[0051] Table 1 Cytotoxic activity test results of compounds 2a-2d and forskolin

[0052]

[0053] As shown in Table 1, the forskolin oxy-bridged ring derivatives provided by the present invention have important biological activities. In vitro cytotoxic activity tests on three types of tumor cells, namely human esophageal cancer cells (TE-13), human colon cancer cells (HCT-116), and human lung adenocarcinoma cells (A549), show that the forskolin oxy-bridged ring derivatives with the structure shown in formula (1) have an inhibitory effect on tumor cell growth and may be developed into new tumor prevention and treatment drugs. From the above pharmacological examples, we can see that these compounds show strong cytotoxic activity on these three types of tumor cells, and the cytotoxic activity exceeds that of forskolin, and have the potential to be developed into anti-tumor drugs.

[0054] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. An oxygen-bridged ring derivative of forskolin, It is characterized in that The structure of the forskolin oxygen bridged ring derivative is shown in the following formula: Here, R represents one of phenyl, p-chlorophenyl, p-methoxyphenyl, p-trifluoromethoxyphenyl, p-tert-butylphenyl, p-methylphenyl, p-nitrophenyl and p-cyanophenyl.

2. A forskolin oxygen-bridged ring derivative according to claim 1, It is characterized in that The forskolin oxy-bridged ring derivative has a structure as shown in any one of Formulas 2a to 2d:

3. A method for preparing the oxygen-bridged ring derivative of forskolin according to claim 1, It is characterized in that The reaction formula of the preparation method is shown below: The preparation method comprises the following steps: S1. Potassium hydroxide was dissolved in methanol, and forskolin was added to react to obtain a first reaction solution. The reaction temperature was 65°C. The first reaction solution was cooled, concentrated under reduced pressure, diluted with an organic solvent, washed with water, washed with saturated brine, and washed with anhydrous MgSO 4 Drying, drying under reduced pressure, and then flash column chromatography to obtain a white solid forskolin rearrangement product 1, wherein the molar ratio of forskolin to potassium hydroxide is 1:13; S2. Dissolving the forskolin rearrangement product 1 in anhydrous dichloroethane, and sequentially adding anhydrous silver acetate, anhydrous copper acetate, palladium acetate and aryl iodide to react at a reaction temperature of 72° C. to obtain a second reaction solution, cooling the second reaction solution, diluting it with an organic solvent, filtering it, concentrating the filtrate under reduced pressure, and then flash column chromatography to obtain a white solid forskolin oxygen bridged ring derivative 2, wherein the molar ratio of the forskolin rearrangement product 1, anhydrous silver acetate, anhydrous copper acetate, palladium acetate and aryl iodide is 1:1.2:2:0.05:2; Wherein, the aryl iodide is one of iodobenzene, p-chloroiodobenzene, p-methoxyiodobenzene, p-trifluoromethoxyiodobenzene, p-tert-butyliodobenzene, p-methyliodobenzene, p-nitroiodobenzene and p-cyaniodobenzene.

4. The preparation method according to claim 3, It is characterized in that In the step S1, the reaction time is 4 hours.

5. The preparation method according to claim 3, It is characterized in that In step S2, the reaction time is 18 hours.

6. The preparation method according to claim 3, It is characterized in that The organic solvent is at least one of ethyl acetate, dichloromethane and dichloroethane.